Compare NFE & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NFE | ARMP |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | 61 |
| Industry | Oil/Gas Transmission | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 295.5M |
| IPO Year | 2018 | 1996 |
| Metric | NFE | ARMP |
|---|---|---|
| Price | $0.69 | $8.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $5.50 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 6.1M | 73.3K |
| Earning Date | 04-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,504,037,000.00 | N/A |
| Revenue This Year | $110.34 | N/A |
| Revenue Next Year | $3.54 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.56 | $1.74 |
| 52 Week High | $4.96 | $14.98 |
| Indicator | NFE | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 46.34 | 37.57 |
| Support Level | $0.59 | $7.43 |
| Resistance Level | $0.77 | $12.11 |
| Average True Range (ATR) | 0.07 | 1.12 |
| MACD | 0.01 | -0.22 |
| Stochastic Oscillator | 25.87 | 14.20 |
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.